Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Mar 23, 2019, 14:00 ET Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study

Sojournix, a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of...


Mar 23, 2019, 14:00 ET Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Oral semaglutide 7 mg and 14 mg demonstrated superior A1C and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for...


Mar 22, 2019, 08:35 ET Eisai to Present Latest Research about Alzheimer's Disease/Dementia Pipeline at The 14th International Conference on Alzheimer's & Parkinson's Diseases

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's...


Mar 22, 2019, 08:30 ET Initiation Of Phase III Clinical Trial Of BAN2401 In Early Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401,...


Mar 22, 2019, 03:48 ET Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe

Moberg Pharma AB (OMX: MOB) has completed the recruitment of 452 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in...


Mar 21, 2019, 19:58 ET BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401...


Mar 21, 2019, 16:01 ET Innovation Is Finally Modernizing Clinical Trials

There is a well-known saying in the Pharmaceutical industry when confronted about the approach to executing and managing clinical trials. It is also...


Mar 21, 2019, 14:47 ET Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease

Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision TORONTO and...


Mar 21, 2019, 14:29 ET Blackfynn announces an expanded partnership with The Michael J. Fox Foundation, extends its neurodegenerative disease data ecosystem and Dr. Karl Kieburtz joins as Head of Clinical Development

Blackfynn, a technology-driven, life-sciences company building the gold-standard data ecosystem in neurodegenerative disease and using its novel data ...


Mar 21, 2019, 14:05 ET High-Fructose Corn Syrup Promotes Colon Tumor Growth in Mice

Consuming the equivalent of one can of soda per day caused mice predisposed to colon cancer to develop larger tumors, according to a study by Weill...


Mar 21, 2019, 09:55 ET Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease

Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including...


Mar 21, 2019, 09:00 ET Point-of-care Diagnostic for Preeclampsia shown Superior to Current Practice

GestVision, Inc., a privately-held biotechnology company, applauds the diligent work of the clinical researchers who conducted the first prospective...


Mar 21, 2019, 08:43 ET Brain Cancer Study of Viral and Checkpoint Immunotherapy Initiates Accrual

Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a study of its Gene Mediated...


Mar 21, 2019, 08:18 ET Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and...


Mar 21, 2019, 08:17 ET Ghent University Scientists Use 'VAMS™' from Neoteryx to Measure a Novel Biomarker for Alcohol Abuse

Neoteryx LLC is supplying its Volumetric Absorptive Microsampling (VAMS™) technology, in the form of the Mitra® microsampling device, to Dr....


Mar 21, 2019, 08:00 ET Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a...


Mar 21, 2019, 08:00 ET PolarityTE Hosts Symposium Featuring SkinTE-Treated Burn Survivor, New Clinical Data at American Burn Association Annual Meeting

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today ...


Mar 21, 2019, 08:00 ET Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer

Epic Sciences, Inc. announced today that new data will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2019, in...


Mar 21, 2019, 08:00 ET DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis

DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in...


Mar 21, 2019, 07:00 ET Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations

Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare diseases, today...


Mar 21, 2019, 07:00 ET Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today that all participants have ...


Mar 21, 2019, 06:21 ET Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has received a clearance from the...


Mar 20, 2019, 19:20 ET Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines,...


Mar 20, 2019, 14:59 ET AlloSource Announces First Patient Enrolled In ProChondrix CR Cartilage Defect Study

AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced it has...


Mar 20, 2019, 10:08 ET Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes

Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide,...